H.C. Wainwright Downgrades CalciMedica (CALC) to Neutral Jan 29, 2026 06:05AM
Oppenheimer Reiterates CalciMedica (CALC) at Outperform, 'We would build a position' Dec 2, 2025 06:09AM
CalciMedica (CALC) Misses Q3 EPS by 52c Nov 12, 2025 04:48PM
CalciMedica partners with Telperian for AI analysis of drug trials Oct 14, 2025 07:01AM
CalciMedica (CALC) Announces Publication in the American Journal of Nephrology Discussing Design and Rationale of Phase 2 KOURAGE Trial of Auxora™ in AKI with Respiratory Failure Jun 25, 2025 07:02AM


May 14, 2025 05:03PM CalciMedica (CALC) Misses Q1 EPS by 36c
Apr 1, 2025 06:50AM H.C. Wainwright Reiterates Buy Rating on CalciMedica (CALC)
Mar 5, 2025 07:01AM CalciMedica (CALC) Secures Credit Facility for Up to $32.5 Million
Mar 4, 2025 07:02AM CalciMedica (CALC) Presents AKI Data from a Post-Hoc Analysis of the Phase 2 CARDEA trial of Auxora
Jan 14, 2025 07:02AM CalciMedica (CALC) Appoints Alan Glicklich to its Board
Nov 7, 2024 07:01AM CalciMedica (CALC) Appoints Stephen Bardin as CFO
Nov 4, 2024 06:47AM CalciMedica (CALC) PT Lowered to $16 at H.C. Wainwright
Oct 30, 2024 04:51PM CalciMedica (CACL) Announces Proposed Share Offering
Oct 30, 2024 07:09AM CalciMedica (CALC) to Present Late-Breaking Positive Data, Including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP) at the American College of Gastroenterology
Aug 14, 2024 06:48AM Oppenheimer Reiterates Outperform Rating on CalciMedica (CALC)
Aug 13, 2024 04:09PM CalciMedica (CALC) Misses Q2 EPS by 36c
Jul 10, 2024 07:36AM CalciMedica (CALC) PT Raised to $20 at Oppenheimer
Jun 28, 2024 02:36PM CalciMedica (CALC) PT Raised to $11.25 at Singular Research, 'Reiterating our Buy-Venture rating'
Jun 28, 2024 06:47AM Oppenheimer Reiterates Outperform Rating on CalciMedica (CALC)
Jun 28, 2024 06:43AM H.C. Wainwright Reiterates Buy Rating on CalciMedica (CALC)
Jun 27, 2024 02:54PM CalciMedica (CALC) PT Lowered to $15 at Jones Trading
Jun 27, 2024 08:03AM CalciMedica (CACI) Reports Positive Topline Data from Phase 2b CARPO Trial of Auxora